Veru (VERU) Stock Forecast, Price & News

Veru (NASDAQ:VERU) Frequently Asked Questions

Is Veru a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veru in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Veru stock.
View analyst ratings for Veru or view top-rated stocks.

Are investors shorting Veru?

Veru saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 14,430,000 shares, an increase of 31.9% from the April 15th total of 10,940,000 shares. Based on an average daily trading volume, of 17,320,000 shares, the short-interest ratio is presently 0.8 days. Approximately 22.4% of the shares of the stock are short sold.
View Veru's Short Interest.

When is Veru's next earnings date?

Veru is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Veru.

How were Veru's earnings last quarter?

Veru Inc. (NASDAQ:VERU) posted its quarterly earnings data on Thursday, May, 12th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.02. Veru had a negative trailing twelve-month return on equity of 18.64% and a negative net margin of 45.56%. During the same period in the previous year, the business posted ($0.04) earnings per share.
View Veru's earnings history.

What price target have analysts set for VERU?

5 Wall Street analysts have issued 1 year price targets for Veru's stock. Their forecasts range from $24.00 to $55.00. On average, they expect Veru's stock price to reach $35.40 in the next year. This suggests a possible upside of 164.6% from the stock's current price.
View analysts' price targets for Veru or view top-rated stocks among Wall Street analysts.

Who are Veru's key executives?

Veru's management team includes the following people:

• Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D., Chairman, Pres & CEO (Age 61, Pay $1.43M)
• Dr. Harry Fisch F.A.C.S., M.D., Vice Chairman & Chief Corp. Officer (Age 63, Pay $648.12k)
• Ms. Michele Greco, CFO & Chief Admin. Officer (Age 63, Pay $659.62k)
• Dr. K. Gary Barnette Ph.D., Chief Scientific Officer (Age 54, Pay $636.7k)
• Mr. Samuel Fisch, Exec. Director of Investor Relations & Corp. Communications
• Mr. Michael J. Purvis, Exec. VP, Gen. Counsel & Corp. Strategy and Sec.
• Mr. Kevin J. Gilbert CPA, J.D., Exec. VP of Corp. Devel.
• Dr. Robert H. Getzenberg Ph.D., Exec. VP for Medical Affairs
• Dr. Domingo Rodriguez, Exec. VP of Clinical Operations (Age 60)
• Mr. Gary Bird Ph.D., Sr. VP of Quality Oversight

Who are some of Veru's key competitors?

Some companies that are related to Veru include Estée Lauder Companies (EL), Prestige Consumer Healthcare (PBH), Herbalife Nutrition (HLF), Inter Parfums (IPAR), Nu Skin Enterprises (NUS), Medifast (MED), USANA Health Sciences (USNA), Nature's Sunshine Products (NATR) and Revlon (REV).
View all of VERU's competitors.

What other stocks do shareholders of Veru own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), OrganiGram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

Who are Veru's major shareholders?

Veru's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.14%), Vanguard Group Inc. (3.93%), State Street Corp (1.45%), Northern Trust Corp (0.73%), Blair William & Co. IL (0.41%) and Royal Bank of Canada (0.32%). Company insiders that own Veru stock include Harry Fisch, K Gary Barnette, Lucy Lu, Michele Greco and Mitchell Shuster Steiner.
View institutional ownership trends for Veru.

Which institutional investors are selling Veru stock?

VERU stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Jane Street Group LLC, UBS Group AG, Northern Trust Corp, JPMorgan Chase & Co., GSA Capital Partners LLP, Cutler Group LP, and MetLife Investment Management LLC.
View insider buying and selling activity for Veru or view top insider-selling stocks.

Which institutional investors are buying Veru stock?

VERU stock was acquired by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Vanguard Group Inc., Graham Capital Management L.P., State Street Corp, Prudential Financial Inc., Renaissance Technologies LLC, Belvedere Trading LLC, and Walleye Capital LLC. Company insiders that have bought Veru stock in the last two years include Harry Fisch, Lucy Lu, and Michele Greco.
View insider buying and selling activity for Veru or or view top insider-buying stocks.

How do I buy shares of Veru?

Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $13.38.

How much money does Veru make?

Veru has a market capitalization of $1.07 billion and generates $61.26 million in revenue each year. The company earns $7.39 million in net income (profit) each year or ($0.340010) on an earnings per share basis.

How many employees does Veru have?

Veru employs 252 workers across the globe.

What is Veru's official website?

The official website for Veru is www.veruhealthcare.com.

How can I contact Veru?

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company can be reached via phone at (305) 509-6897, via email at [email protected]a.com, or via fax at 312-595-9122.